Designing CAR T cells for glioblastoma

OncoImmunology

Volumn 4, Issue 12, 2015, Pages

  Maus, Marcela V ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adoptive cell therapy; CAR T cells; EGFRvIII; glioblastoma

Indexed keywords

CD19 ANTIGEN; CETUXIMAB; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LENTIVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CHIMERIC ANTIGEN RECEPTOR MODIFIED T LYMPHOCYTE; CONTROLLED STUDY; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TOXICITY; TUMOR XENOGRAFT;

EID: 84944569270     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1048956     Document Type: Article

References (10)

1. D.L.Porter, B.L.Levine, M.Kalos, A.Bagg, C.H.June. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
2. S.A.Grupp, M.Kalos, D.Barrett, R.Aplenc, D.Porter, S.Rheingold, D.Teachey, A.Chew, B.Hauck, J.Wright, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa1215134
3. S.L.Maude, N.Frey, P.A.Shaw, R.Aplenc, D.M.Barrett, N.J.Bunin, A.Chew, V.E.Gonzalez, Z.Zheng, S.F.Lacey, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
4. C.H.J.Lamers, S.Sleijfer, A.G.Vulto, W.H.J.Kruit, M.Kliffen, R.Debets, J.W.Gratama, G.Stoter, E.Oosterwijk. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24:e20-2; PMID:16648493; http://dx.doi.org/10.1200/JCO.2006.05.9964
5. R.A.Morgan, J.C.Yang, M.Kitano, M.E.Dudley, C.M.Laurencot, S.A.Rosenberg. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24
6. R.A.Morgan, N.Chinnasamy, D.Abate-Daga, A.Gros, P.F.Robbins, Z.Zheng, M.E.Dudley, S.A.Feldman, J.C.Yang, R.M.Sherry, et al. Cancer regression and neurological toxicity following Anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36:133-51; PMID:23377668; http://dx.doi.org/10.1097/CJI.0b013e3182829903
7. G.P.Linette, E.A.Stadtmauer, M.V.Maus, A.P.Rapoport, B.L.Levine, L.Emery, L.Litzky, A.Bagg, B.M.Carreno, P.J.Cimino, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122:863-71; PMID:23770775; http://dx.doi.org/10.1182/blood-2013-03-490565
8. B.J.Cameron, A.Gerry, J.Dukes, J.V.Harper, V.Kannan, F.C.Bianchi, F.Grand, J.Brewer, M.Gupta, G.Plesa, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013; 5(197):197ra103
9. L.A.Johnson, R.A.Morgan, M.E.Dudley, L.Cassard, J.C.Yang, M.S.Hughes, U.S.Kammula, R.E.Royal, R.M.Sherry, J.R.Wunderlich, et al. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535-46; PMID:19451549; http://dx.doi.org/10.1182/blood-2009-03-211714
10. L.A.Johnson, J.Scholler, T.Ohkuri, A.Kosaka, P.R.Patel, S.E.McGettigan, A.K.Nace, T.Dentchev, P.Thekkat, A.Loew, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 2015; 7:275ra22; PMID:25696001; http://dx.doi.org/10.1126/scitranslmed.aaa4963